🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

2/90 pts (2.2%) in GEM-CESAR died of SPMs!! IMO, OS benefit against a control arm of observation followed by treatment at NDMM should be demonstrated for changing practice. We have modern imaging tools (eg WB DW-MRI) to detect focal lesions early before fractures #ASH22 #mmsm

master presenter Ajai Chari presenting Talquetamab a bispecific antibody targeting GPRC5D. Amazing 74% ORR and even more remarkable low infection rates grade 3/4 at 17% and 12%. This is remarkable and may likely be the next bispecific and First GPRC5D available #ASH22 #MedIQ22ASH

Cevostamab is the first bispecific to show durable results with fixed duration rather than continuous therapy. Median DOR is 11.1 months with median time on therapy 8.8 months. Infections are the “Achilles heel” of bispecifics. So longer intervals between doses is key! #ASH22

Chromosome 1q- We are starting to understand which genes drive adverse risk. Copy number changes, regions of gain and templated insertion occur and overlap with known driver genes. 2/3 of cases are whole arm gain jumping translocations. Eileen M. Boyle #ASH22

Modakfusp innate immunity enhancer in relapsed refractory MM patients shows preliminary efficacy at 1.5 mg IV q4 weeks even in patients refractory to anti-cd38 antibody and prior exposure to an anti-bcma therapy. Phase 1/2 data presented by Dr. Vogl. #ASH22

Lower rates of CRS seen with prophylactic tocilizumab IL-6 mo-Ab in RRMM patients receiving the BCMA/CD3 bispecific cevostamab by interfering with IL-6 signaling . No observed negative impact on efficacy compared to retrospective control. Watch for neutropenia. #ASH22

nejm.org/doi/full/10.10… Congratulations to the authors on some fantastic data and grateful to see more therapy with a meaningful response for our patients with relapsed refractory myeloma! Will talq be the bi-specific of choice? Ajai Chari #ASH22

3.3% infection-related deaths with Dara-KRD in Smoldering #Myeloma. Follow-up not long enough for SPMs (2.2% Fatal SPMs in GEM-CESAR!!). Given dismal 4-year sustained MRD-neg in GEM-CESAR (23%), long-term follow up need to see if MRD-neg rate holds up after Rx stops!! #ASH22

Our FREE patient summit is happening THIS week! Our expert panel: Dr. David Vesole, Dr. Kimberly Doucette, & Noa Biran will provide the most up-to-date information on #myeloma management. Don’t miss out – register today: ow.ly/yIjs50N5j3n JTCancerCenter MedStar Washington #mmsm

$KPTI Seli Phase 2b + Carfilzomib, Dara or Pom by Noa Biran QT: Stage III MM + high risk cyto, 93% refractory to last line of treatment, 47% triple refractory (!). Pts enrolled if Refractory to specific drug. Seli + Spec Drug = 92% Clinical Benefit Rate contd/

Heading to #ASCO23? Join Robert Z. Orlowski, Ajay Nooka, MD, MPH, and I for a #MultipleMyeloma MasterClass & Case Forum on 6/ 3 in Chicago! bit.ly/3nQJVSc #Immunotherapy #MedEd #MedTwitter @HealthtreeMM PeerView

Dr. Yael Cohen presents combination teclistimab and talquetembab in triple class exposed, median 4 prior lines, 1/3rd soft tissue EMD. 96% ORR! 86% in EMD. Safety profile similar to monotherapy! 👍💪fantastic! ASCO

Next generation CAR T cells PHE885 presented by Dr. Adam Sperling in triple refractory heavily pretreated RRMM patients, 33% with EMD. 10 day door to door manufacturing time! 100% ORR at active dose. Watch for CRS and ICANs at similar rates to approved CAR T. #ASCO23

Ivan Borello conveys a variety of approaches being used to improve therapeutic efficacy of CAR T. One strategy is to maximize T cell persistence, reduce T cell exhaustion, enhance T cell stemness, and treat earlier in the disease setting. #ASCO2023

Post T cell redirecting therapy setting options: data shows that GPRC5D remains a viable antigen target. Early studies support the first GPRC5D CAr-T and shows a median 12.7 month DOR with talquetemab in these patients! Presented by Dr. Paula Rodriguez-Otero. #ASCO2023

First GPRC5D targeted therapy approved for patients with multiple myeloma!! 70% response rate including in patients who had prior BCMA -directed therapy. pharmaceutical-technology.com/news/fda-appro…

Don’t miss our FREE one-hour webinar on 2/14! #Myeloma experts, Drs. Noa Biran and Gurbakhash Kaur, will discuss bispecific antibodies used in #multiplemyeloma treatment. Register today: ow.ly/VoY950QvH5t #mmsm

No OS Survival Benefit with Lenalidomide Maintenance. Real world data evaluating 1928 transplant eligible MM patients showed median OS from time of ASCT 108 mos with maintenance vs 126 mos with NO maintenance. P=0.09. Congrats Dr. Parmar! Harsh Parmar MD

tandfonline.com/eprint/PGZMQTF…

sciencedirect.com/science/articl…